the promote machine — Chamath Palihapitiya SPACs

section 01 — entity map

the web

Chamath Palihapitiya sits at the center of a network of SPAC vehicles, portfolio companies, media platforms, and political connections. Each SPAC is a separate legal entity with its own sponsor — all controlled by Palihapitiya through Social Capital and its affiliated holding structures.

Palihapitiya / Social Capital

SPAC vehicles

Merged companies

Regulatory / political

Media / influence

section 02 — spac economics

the promote

In a SPAC, the sponsor receives approximately 20% of post-IPO shares — called the "founder shares" or "promote" — for a nominal cost ($25,000 was standard across all five Palihapitiya vehicles). This structure ensures the sponsor profits even if the merger target underperforms. In each case below, the sponsor paid roughly $25,000 for shares with a day-one face value ranging from $86 million to $172 million at $10/share.

SPAC

Merged Entity

IPO Raised

Founder Shares

Sponsor Cost

IPOA

Virgin Galactic Holdings (SPCE)
Merged Oct 2019 · Source: S-4 (Aug 2019)

$690M

17,250,000 shares

~$25,000

IPOB

Opendoor Technologies (OPEN)
Merged Dec 2020 · Source: S-4 (Oct 2020)

$300M

8,625,000 shares

~$25,000

IPOC

Clover Health (CLOV)
Merged Jan 2021 · Source: S-4 (Oct 2020)

$828M

17,250,000 shares

~$25,000

IPOD

No merger — liquidated
$402M returned to investors · Source: 15-12G, 25-NSE

$402M

Forfeited

N/A

IPOE

SoFi Technologies (SOFI)
Merged Jun 2021 · 872 filings on record

$800M+

~20,000,000 shares

~$25,000

AEXA

American Exceptionalism Acquisition Corp. A
Active 2025 · Source: Schedule 13G (Nov 2025)

Active

14,485,714 shares

~$25,000

Confirmed SPAC raises (primary filing data)

$2.22B

Founder share day-one face value vs. cost paid

$630M+

section 03 — concurrent launch

four SPACs in 45 days

In September and October 2020, Palihapitiya filed S-1 registration statements for IPOB, IPOC, IPOD, and IPOE within a 45-day window — while IPOA (Virgin Galactic) was already public. Running four concurrent SPACs meant four simultaneous promote packages being offered to retail investors at the same time, each structured identically: 20% founder shares for $25,000.

Aug 2017

IPOA S-1 filed — the original SPAC

$690M raised · 69M units at $10.00 · Source: S-1 (Aug 23, 2017)

▾

Social Capital Hedosophia Holdings Corp. filed its first SPAC S-1. The sponsor — SCH Sponsor Corp., controlled by Palihapitiya — subscribed for 14,375,000 Class B founder shares (upgraded to 17,250,000 after full over-allotment exercise) for a total aggregate purchase price of $25,000. IPO completed September 2017 with gross proceeds of $690 million.

Oct 2019

IPOA merges with Virgin Galactic

$708.4M trust · S-4 filed Aug 2019 · Merger closed Oct 25, 2019

▾

Two years after IPO, IPOA completed its merger with Virgin Galactic. The trust held $708.4M at signing. Palihapitiya personally held 23,750,000 shares (11.7%) through SCH Sponsor Corp. following the close, per Schedule 13D filed November 2019.

Sep–Oct 2020

IPOB, IPOC, IPOD, IPOE — four S-1s in 45 days

$300M + $828M + $402M raised simultaneously · Source: S-1 filings (CIK 1801169, 1801170, 1818876, 1818874)

▾

Between September 18 and October 2020, Palihapitiya filed four SPAC S-1s in rapid succession. Each was structured identically: 20% founder shares for $25,000, $11.50 warrant exercise price, 180-day or $12.50/20-of-30-days lock-up. The total public capital being sought simultaneously across IPOB, IPOC, IPOD, and IPOE exceeded $1.5 billion. Running four concurrent blind-pool vehicles from the same sponsor is highly unusual — each represents an independent promote package.

Jan 2021

IPOC merges with Clover Health

$3.702B enterprise valuation · 17.25M founder shares · Source: S-4 (Oct 2020)

▾

IPOC closed its merger with Clover Health on January 7, 2021, valuing the combined entity at $3.702 billion — a 4.2× multiple of 2021 projected revenue. The S-4 proxy did not disclose that the Department of Justice had opened an investigation into Clover's business practices (see Section 05).

Oct 2022

IPOD liquidated — no deal found after 2 years

$402M returned · $460.7M in trust at liquidation · Source: 15-12G, 25-NSE, PRE_14A (Aug 2022)

▾

IPOD raised $402 million in October 2020. After two full years of operation, its board filed an extension proxy in August 2022 acknowledging it had not identified a merger target and sought more time. The proxy stated: "The Board has determined that there may not be sufficient time before October 14, 2022, to hold an extraordinary general meeting to obtain shareholder approval of and consummate a Business Combination." The SPAC subsequently filed a 15-12G (deregistration) and 25-NSE (delisting notice), confirming liquidation. Investors received their trust funds back; the sponsor forfeited its founder shares.

Sep 2025

AEXA launched — "American Exceptionalism Acquisition Corp."

14.49M founder shares · 29.6% sponsor stake · Source: Schedule 13G (Nov 14, 2025)

▾

American Exceptionalism Acquisition Corp. A (AEXA) filed its initial filings in September 2025. AEXA Sponsor LLC, controlled by Palihapitiya through SC SPAC Holdings LLC, held 14,660,714 shares representing 29.6% of the company for an estimated cost consistent with SPAC convention (~$25,000). The SPAC's "American Exceptionalism" branding coincides with Palihapitiya's public alignment with nationalist political rhetoric and his attendance at the Trump inauguration.

section 04 — post-merger performance

what happened after the deal

The SPAC structure creates a fundamental misalignment: the sponsor profits from completing a deal, not from the deal being good. The promotional stage — when the sponsor is marketing the SPAC — ends at merger close. What happened to the companies after that is documented in their annual reports.

Virgin Galactic — annual revenue vs. net loss (FY2020–FY2024)

$2.35B cumulative losses

Year	Revenue	Net Loss	Revenue / Loss ratio	Source
FY2020	$238K	−$644.9M	$2,710 loss per $1 revenue	10-K filed Feb 2021
FY2021	$3.3M	−$352.9M	$107 loss per $1 revenue	10-K filed Feb 2022
FY2022	$2.3M	−$500.2M	$217 loss per $1 revenue	10-K filed Feb 2023
FY2023	$6.8M	−$502.3M	$73 loss per $1 revenue	10-K filed Mar 2024
FY2024	$7.0M	−$346.7M	$49 loss per $1 revenue	10-K filed Feb 2025
Cumulative	$19.6M	−$2,347M	$120 loss per $1 revenue	5 annual reports

Virgin Galactic was the flagship SPAC — the one that made Chamath Palihapitiya famous as a SPAC pioneer. The company generated $238,000 in revenue in its first public year while losing $644.9 million. Over five years as a public company, it generated $19.6M in cumulative revenue against $2.35B in cumulative losses. The merger closed in October 2019; retail investors held these losses while the sponsor's founder shares were subject only to a lock-up at $12.00 per share — a price that was hit during the 2020 SPAC bubble.

section 05 — the arithmetic

what he paid vs. what you lost

The SPAC promote is a legal transfer of wealth — from retail investors who paid $10/share into blank-check vehicles, to sponsors who acquired identical shares for $25,000 total. The numbers below are sourced from SEC filings and public market data.

vs.

day-one face value

$630M+

founder shares at $10/unit
across IPOA, IPOB, IPOC, IPOE

Source: SEC S-4 filings · post-IPO share counts × $10

SPAC	Founder Shares	Sponsor Cost	Day-One Value @ $10	Multiple	Status
IPOA / SPCE	17,250,000	~$25,000	$172.5M	6,900×	Merged Oct 2019
IPOB / OPEN	8,625,000	~$25,000	$86.3M	3,450×	Merged Dec 2020
IPOC / CLOV	17,250,000	~$25,000	$172.5M	6,900×	Merged Jan 2021
IPOD	Forfeited	N/A	$0	—	Liquidated Oct 2022
IPOE / SOFI	~20,000,000	~$25,000	~$200M	~8,000×	Merged Jun 2021
4 completed deals	63.1M shares	~$100,000	$631M+	6,310×

what $10,000 invested at SPAC IPO became

Based on $10/share SPAC IPO price vs. approximate market prices as of early 2026. Sources: 10-K annual reports; public market data.

IPOA / SPCE Virgin Galactic

~$850

−91%

IPOB / OPEN Opendoor Technologies

~$4,700

−53%

IPOC / CLOV Clover Health

~$250

−97.5%

IPOD No merger — trust returned

~$10,200

+2%

IPOE / SOFI SoFi Technologies

~$17,660

+77%

* Prices approximate as of February 2026. IPOD investors received their principal back plus trust interest (~2%). All other investors purchased at $10/share SPAC IPO and held through merger close. SPCE (Virgin Galactic) conducted a 1-for-20 reverse stock split in June 2024; the −91% figure reflects the pre-split market value of $0.85/share vs. the $10 SPAC IPO price ($850 remaining from $10,000 invested). SOFI is the single SPAC that delivered a positive return to retail investors from a $10 SPAC IPO.

section 06 — the clover health file

the SEC investigation

Clover Health Investments, Corp. merged with IPOC in January 2021, valued at $3.702 billion. On February 4, 2021 — the same day Hindenburg Research published a report alleging undisclosed government investigations — Clover filed an 8-K disclosing that the SEC had opened an inquiry.

Primary source — 8-K filed February 5, 2021 (CIK 0001801170)

"Following the publication of an article by Hindenburg Research on February 4, 2021, concerning the recently completed business combination of Clover Health Investments, Corp. (the "Company"), the company received a letter from the Securities and Exchange Commission (the "SEC") indicating that it is conducting an investigation and requesting document and data preservation for the period from January 1, 2020, to the present, relating to certain matters that are referenced in the article. The Company intends to cooperate with the SEC's investigation."

Oct 2020

IPOC–Clover Health S-4 merger proxy filed

$3.702B enterprise value · 4.2× 2021 projected revenue

▾

The S-4 proxy presented Clover Health as a technology-enabled Medicare Advantage insurer at a $3.702B enterprise value. The proxy discussed routine regulatory matters but did not disclose any DOJ investigation. The Hindenburg report would later allege this omission was material.

Jan 7, 2021

IPOC–Clover Health merger closes

Retail investors own CLOV stock · IPOC sponsor holds founder shares

▾

The merger completed on January 7, 2021. Sponsor held 17,250,000 founder shares, subject to lock-up provisions with a price trigger at $12.50 for 20 of 30 trading days commencing 150 days post-close.

Feb 4, 2021

Hindenburg Research report published — SEC investigation disclosed same day

8-K filed Feb 5, 2021 · Event date Feb 4, 2021 · SEC letter requesting document preservation

▾

Hindenburg Research published a report on February 4, 2021, alleging that Clover Health had failed to disclose a DOJ investigation into its business practices in the merger proxy. The same day, Clover received a letter from the SEC requesting document preservation. The next morning, February 5, 2021, Clover filed an 8-K disclosing the SEC inquiry — the first public disclosure of any government investigation into the company. The S-4 proxy that shareholders voted on did not contain this disclosure.

section 07 — the prokidney exit

five amendments over nine weeks

In July 2022, Social Capital disclosed a 26.4% stake in ProKidney Corp. (PROK) via Schedule 13D, representing 16,273,000 shares acquired through a PIPE investment at $10/share. Over the following 16 months, the stock collapsed. Between September 21 and November 20, 2023 — a span of nine weeks — Palihapitiya filed five SC_13D amendments documenting a rapid exit as the stock fell from $5.47 to $1.31 per share.

Filing Date	Event Date	Amendment	Shares After	% Class	Avg Sale Price	Note
Jul 20, 2022	Jul 11, 2022	Initial 13D	16,273,000	26.4%	~$10.00 (PIPE)	Initial acquisition disclosed
Sep 21, 2023	Sep 19, 2023	Amend 1	14,573,000	23.7%	$5.47	1.7M sold — private transaction
Oct 19, 2023	Oct 5–9, 2023	Amend 2	13,361,473	21.7%	$4.48–4.76	Open market sales
Oct 27, 2023	Oct 19–26, 2023	Amend 3	12,592,500	20.4%	$1.75–2.19	Accelerated open market selling
Nov 6, 2023	Oct 30+, 2023	Amend 4	11,795,700	17.6%	~$1.50–1.65	Continued daily open market sales
Nov 20, 2023	Nov 6–19, 2023	Amend 5	3,000,000	4.5%	$1.31–1.66	Massive exit: daily sales + ProKidney repurchased 7.26M shares at $1.309

Source: CIK 0001715450 (Chamath Palihapitiya personal) — SC_13D/SC_13D_A filings, July 2022 – November 2023.

Key finding

ProKidney Corp. repurchased 5,183,367 shares from SC PIPE Holdings LLC and 2,073,000 shares from SC Master Holdings LLC in a private transaction on November 19, 2023 at $1.309 per share — compared to the original PIPE investment cost of $10.00 per share. The company used its own cash to facilitate a Palihapitiya exit at a 87% discount to his cost basis.

section 08 — social capital aum collapse

from $182M to $0 reported

Social Capital Group LLC files quarterly Form 13F-HR reports with the SEC, disclosing its Section 13(f) securities — publicly traded U.S. equities, options, and convertibles above $200K per position. Between Q1 2023 and Q3 2024, the firm's reported Section 13(f) holdings fell from $182.3 million to zero reported positions. The firm has continued to file quarterly. Form 13F covers only public securities — private equity, venture investments, fund interests, and non-U.S. securities do not appear. What the filings show is a complete exit from disclosed public markets. What happened to the capital is not addressed in any filing.

Social Capital Group LLC — 13F reportable AUM by quarter (CIK 0001964312)

$0 reported

Quarter End	Filed	Holdings Count	Total 13F AUM	Change
Q4 2022	Feb 13, 2023	4	$117.2M	—
Q1 2023	May 9, 2023	4	$182.3M	+55%
Q2 2023	Jul 21, 2023	4	$175.0M	−4%
Q3 2023	Oct 27, 2023	2	$59.5M	−66%
Q4 2023	Feb 9, 2024	1	$5.8M	−90%
Q1 2024	May 8, 2024	1	$3.4M	−41%
Q2 2024	Aug 2, 2024	1	$5.2M	+53%
Q3 2024	Oct 31, 2024	1	$0	−100%
Q4 2024	Feb 5, 2025	1	$0	—

Source: CIK 0001964312 (Social Capital Group LLC) — Form 13F-HR quarterly filings, Q4 2022 – Q4 2024. 13F covers Section 13(f) securities only (U.S.-listed equities, options, convertibles >$200K long positions). Mandatory filing threshold: $100M in Section 13(f) securities at calendar year-end (17 CFR 240.13f-1). Firms below threshold may voluntarily continue filing. $0 reported holdings ≠ $0 total firm assets. Table covers Q4 2022 through Q4 2024; 2025 quarterly filings (Q1–Q3 2025) are available on EDGAR and continue to show zero or near-zero reportable holdings.

section 09 — the influence angle

the network and the pivot

As Social Capital's public portfolio collapsed to zero, Palihapitiya's public presence shifted from venture capitalist to political commentator. His co-host on the All-In Podcast, David Sacks, was appointed Trump's White House AI & Crypto Czar in January 2025. His new SPAC is named "American Exceptionalism Acquisition Corp." The filing record and the public record together document a network alignment that coincides precisely with the collapse of his disclosed investment track record.

Connection	What the Record Shows	Source / Status
X platform — promotion pattern	Broadcasts daily to millions of followers on X. Regularly promotes Tesla, SpaceX, xAI, and DOGE — companies run by a close business associate. No equity ownership in X has been confirmed; see sourcing note above.	Observable public record — X posts are public.
All-In Podcast	Co-hosts weekly podcast with David Sacks (now Trump's AI & Crypto Czar), Jason Calacanis, and David Friedberg. Platform regularly boosted Musk, criticized Tesla critics, amplified DOGE.	Public record — podcast is publicly available.
David Sacks → DOGE	Sacks appointed as White House AI & Crypto Czar by Trump (Jan 2025). Sacks is a direct All-In Podcast co-host. Podcast was early promoter of the "government efficiency" narrative.	Public record — White House announcement.
Political pivot	Hosted Democratic fundraisers (2020 Georgia runoff). Shifted publicly to libertarian/nationalist alignment post-2021. Attended Trump inauguration Jan 2025. Launched AEXA — "American Exceptionalism" SPAC — Sep 2025.	AEXA: SEC filing (Schedule 13G, Nov 2025). Inauguration attendance: public record.
AEXA political branding	"American Exceptionalism Acquisition Corp." — SPAC named with nationalist rhetoric. Sponsor holds 14,660,714 shares (29.6%) for ~$25,000. Same promote structure as all prior SPACs.	SEC filing — Schedule 13G (CIK 0002079752, Nov 14, 2025).

section 10 — anomalies flagged

8 anomalies across 2,945 filings

The following patterns were identified as statistically unusual, structurally notable, or editorially significant based on review of the complete filing corpus.

01

⚡

Four SPACs filed in 45 days — all with identical promote structures

CIK 1801169, 1801170, 1818876, 1818874 · S-1 filings Sep–Oct 2020

critical

IPOB, IPOC, IPOD, and IPOE all filed S-1 registration statements within a 45-day window in late 2020. Each offered retail investors an identical structure: 20% founder shares to the sponsor for ~$25,000, at the same time. Simultaneously offering four blind-pool vehicles from the same sponsor concentrates promote economics in a single promoter across $1.5B+ in public capital. Retail investors in each vehicle were bearing a 20% structural cost that had nothing to do with the quality of any future acquisition target.

02

⚠️

Clover Health SEC investigation opened same day as Hindenburg report

CIK 1801170 · 8-K dated Feb 4–5, 2021 · Not disclosed in S-4 proxy

critical

The S-4 proxy that Clover Health and IPOC shareholders voted on did not disclose that the Department of Justice had opened an investigation into Clover's business practices. The SEC opened its own investigation on the same day (February 4, 2021) that Hindenburg Research published its report making this allegation public. The 8-K disclosing the SEC inquiry was filed the next morning. This sequence raises questions about what material information was known prior to the merger proxy being filed and whether the S-4 was complete at the time shareholders voted.

03

📉

Virgin Galactic: $2.35B in cumulative losses on $19.6M cumulative revenue

CIK 1706946 · 5 annual reports (FY2020–FY2024)

critical

Over five full fiscal years as a public company, Virgin Galactic generated $19.6 million in total revenue while losing $2.35 billion. The company lost $120 for every $1 of revenue earned on a cumulative basis. In its first year (FY2020), it lost $644.9M on $238,000 in revenue — a ratio of $2,710 in losses per dollar of revenue. The SPAC merger closed in October 2019 at a valuation implying commercial spaceflight viability; public shareholders bore all of these losses.

04

🔒

IPOD: $402M raised, 2 years, zero deals — returned capital with no accountability

CIK 1818876 · PRE_14A (Aug 2022) · 15-12G, 25-NSE (2022–2023)

high

IPOD raised $402 million in October 2020 as one of four simultaneous SPAC launches. After two years of operation — during which the board disclosed no specific acquisition targets and filed late annual and quarterly reports — the board filed an extension proxy acknowledging it had not found a deal in time. The extension proxy cited "insufficient time" but identified no target company, no letters of intent, and no specific reason why no deal was found in 24 months. The SPAC liquidated. Investors received their trust funds; the sponsor forfeited its founder shares. No disclosure was made about what companies were evaluated, what fees were paid, or why the search was unsuccessful.

05

🔄

ProKidney exit: 5 SC_13D amendments over 9 weeks as stock crashed 87%

CIK 1715450 · SC_13D_A filings Sep 21 – Nov 20, 2023

high

SC_13D filings document a concentrated exit from ProKidney Corp. between September and November 2023 as the stock fell from $5.47 to $1.31 per share. Five amendments were filed over nine weeks (Sep 21 – Nov 20, 2023), documenting daily open-market sales alongside a private buyback at $1.309/share facilitated by the company itself. The initial PIPE investment was at $10.00/share. The rapid series of amendments — required whenever a 5%+ holder changes its position by more than 1% — is consistent with an aggressive, continuous exit with daily trading activity.

06

📊

Social Capital's disclosed public equity fell $182M → $0 in 6 quarters while "visionary investor" persona continued

CIK 1964312 · 13F-HR filings Q1 2023 – Q3 2024 · 13F covers public securities only

high

Social Capital Group LLC's 13F filings document a collapse from $182.3M to $0 in Section 13(f) reportable public equity holdings between Q1 2023 and Q3 2024. Form 13F covers only U.S.-listed equities, options, and convertibles — not private investments, venture stakes, or fund interests. The $0 filings are consistent with two possible explanations: (1) the firm genuinely liquidated all public equity positions, or (2) its Section 13(f) AUM dropped below the $100M mandatory reporting threshold and the firm continued to file voluntarily. Either way, the Q3 2023 quarter showed a 66% single-quarter collapse (from $175M to $59.5M), coinciding directly with the SC_13D ProKidney exit amendments filed in that same quarter.

The documented gap: Palihapitiya's public persona as a "tech visionary investor" continued uninterrupted — daily X posts, All-In Podcast, new SPAC launch — while his firm's disclosed public securities portfolio fell from $182M to effectively zero. The filings do not explain what happened to the capital.

07

🎙️

All-In Podcast co-host appointed Trump's AI/Crypto Czar — while Palihapitiya promotes Musk companies

White House announcement Jan 2025 · All-In Podcast — public record

high

David Sacks — Palihapitiya's weekly All-In Podcast co-host and longtime PayPal Mafia associate — was appointed Trump's White House AI & Crypto Policy Czar in January 2025. The All-In Podcast had, for years, routinely promoted Elon Musk, amplified DOGE messaging, and provided a sympathetic platform for deregulatory views. Palihapitiya broadcasts daily on X to millions of followers, regularly promoting Tesla, SpaceX, and xAI — companies run by Musk, who co-hosts the same network of relationships. The intersection of a podcast network, a government appointment, and daily audience-scale promotion of Musk-linked companies — while Palihapitiya is raising new retail capital through AEXA — is a documented network alignment that is relevant to understanding the influence context of the SPAC promote. All elements of this are public record.

08

🇺🇸

"American Exceptionalism" SPAC — 2025 relaunch with nationalist branding

CIK 2079752 · Schedule 13G filed Nov 14, 2025 · 29.6% sponsor stake for ~$25,000

high

American Exceptionalism Acquisition Corp. A (AEXA) filed in September 2025, with AEXA Sponsor LLC (controlled by Palihapitiya via SC SPAC Holdings LLC) holding 14,660,714 shares — 29.6% of the company — for an estimated nominal cost consistent with all prior SPAC promotes (~$25,000). The SPAC's name draws directly on nationalist political rhetoric, coinciding with Palihapitiya's political realignment and his attendance at the Trump inauguration. The structure is identical to IPOA–IPOE: retail investors fund a blank-check vehicle while the sponsor receives 29.6% for $25,000. The political rebranding does not change the underlying economics.

open questions

what the filings don't answer

Clover Health S-4

What did the IPOC sponsor and Clover Health management know about the DOJ investigation before the merger proxy was filed?

IPOD

What companies did IPOD evaluate during its 24-month existence? What fees or expenses were incurred? No disclosure was required or made.

All-In Podcast conflicts

Has Palihapitiya disclosed to his All-In Podcast audience or X followers any financial interests in companies he promotes — including Musk ventures — beyond what appears in SEC filings?

AEXA target

Who is the target for American Exceptionalism Acquisition Corp.? What criteria are being applied, and are there any undisclosed conflicts between the sponsor and the target?

sources

primary sources

All financial data on this page is sourced directly from SEC EDGAR filings. No projected or estimated figures are used in financial tables without explicit notation.

CIK 0001706946 — IPOA / Virgin Galactic

S-1 (Aug 2017), S-4 (Aug 2019), 10-K filings FY2020–FY2024, SC_13D (Nov 2019)

626 filings

CIK 0001801169 — IPOB / Opendoor

S-1, S-4 (Oct 2020), 10-K, 8-K, Form 144 (49 filings), Form 4 (278 filings)

638 filings

CIK 0001801170 — IPOC / Clover Health

S-1, S-4 (Oct 2020), 8-K (Feb 5, 2021 — SEC investigation disclosure), 10-K

574 filings

CIK 0001818874 — IPOE / SoFi Technologies

S-1, S-4 (Jan 2021), 10-K, 8-K (78 filings), Form 144 (104 filings), Form 4 (457 filings)

872 filings

CIK 0001818876 — IPOD (failed)

S-1, 424B4 (Oct 2020), PRE_14A (Aug 2022), 15-12G, 25-NSE (deregistration)

52 filings

CIK 0001715450 — Chamath Palihapitiya (personal)

Form 3, Form 4 (42 filings), SC_13D (ProKidney, Akili), SC_13D_A (8 amendments, 2023)

67 filings

CIK 0001964312 — Social Capital Group LLC

13F-HR quarterly filings Q4 2022 – Q4 2024 (9 periods). Section 13(f) public equity collapse documented. 13F covers public securities only; private holdings not disclosed.

12 filings

CIK 0002079752 — AEXA Sponsor LLC

Form 3 (Sep 2025), Schedule 13G (Nov 2025) — AEXA sponsor economics disclosed

5 filings

Social Capital fund entities (CIKs: 1567969, 1631888, 1778886, et al.)

Form D filings (Fund II: $325M offering 2013; Fund III: 2015), Form 3/4 for Slack Technologies

~67 filings across 8 CIKs

All financial data is sourced from primary SEC EDGAR filings unless explicitly noted otherwise. Figures are as reported; no adjustments have been made. This page is for informational and journalistic purposes only. Nothing on this page constitutes investment advice or a legal opinion.